Holen Sie sich die Stockscreener-App
1.35
3.57%
-0.05
Schlusskurs vom Vortag:
$1.40
Offen:
$1.37
24-Stunden-Volumen:
89,035
Relative Volume:
0.21
Marktkapitalisierung:
$81.77M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.86M
KGV:
-1.2054
EPS:
-1.12
Netto-Cashflow:
$-55.66M
1W Leistung:
-14.01%
1M Leistung:
+21.62%
6M Leistung:
-10.00%
1J Leistung:
-58.20%
1-Tages-Spanne:
$1.35
$1.39
1-Wochen-Bereich:
$1.35
$1.6195
52-Wochen-Spanne:
$0.8551
$3.36
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Firmenname
Acumen Pharmaceuticals Inc
Sektor
Branche
Telefon
925-368-8508
Adresse
427 PARK ST., CHARLOTTESVILLE
Vergleichen Sie ABOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.35 | 84.80M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-07-26 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-20 | Fortgesetzt | BofA Securities | Buy |
| 2023-05-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Eingeleitet | BTIG Research | Buy |
| 2022-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-07-26 | Eingeleitet | BofA Securities | Neutral |
| 2021-07-26 | Eingeleitet | Credit Suisse | Outperform |
| 2021-07-26 | Eingeleitet | Stifel | Buy |
| 2021-07-26 | Eingeleitet | UBS | Buy |
Alle ansehen
Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten
How Acumen Pharmaceuticals Inc. stock performs during market volatilityControlled Entry Strategy With Safety Analytics - Newser
Analyzing drawdowns of Acumen Pharmaceuticals Inc. with statistical toolsSmart Money Strategy for Growth Stocks - Newser
What catalysts could drive Acumen Pharmaceuticals Inc. stock higher in 2025Maximize returns with strategic stock selection - jammulinksnews.com
How to monitor Acumen Pharmaceuticals Inc. with trend dashboardsEquity Signal Recap With Long-Term Summary - Newser
Acumen Pharmaceuticals’ Promising Alzheimer’s Study: A Potential Game-Changer? - TipRanks
Using economic indicators to assess Acumen Pharmaceuticals Inc. potentialPredictable Return Strategy with AI Support - Newser
When is Acumen Pharmaceuticals Inc. stock expected to show significant growthWealth Building Picks That Work - jammulinksnews.com
Why is Acumen Pharmaceuticals Inc. stock attracting strong analyst attentionAI Powered Tracker With Low Risk - jammulinksnews.com
How strong is Acumen Pharmaceuticals Inc. company’s balance sheetEntry Signal Guidance With Proven Results - jammulinksnews.com
Using Python tools to backtest Acumen Pharmaceuticals Inc. strategiesPortfolio Review Summary with Five-Year Outlook - Newser
What makes Acumen Pharmaceuticals Inc. stock price move sharplyProfitable Trading Blueprint with Entry Zones - Newser
Has Acumen Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility ReviewStock Entry Points Based on Technicals - Newser
Acumen Pharmaceuticals Inc. Moves Into Bullish Territory Based on MACDAlpha Focused Technical Trade Signals Gain Attention - metal.it
Momentum Screeners Rank Acumen Pharmaceuticals Inc. in Top 5 TodayDaily Chart Pattern Stock Forecast Shows Bullish Setup - beatles.ru
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025 - The Manila Times
40% Trial Cost Cut: Acumen's New Alzheimer's Drug Shows Superior Target Selectivity | ABOS Stock News - Stock Titan
Are Bears Losing Grip on Acumen Pharmaceuticals Inc.Weekly Stock Opportunity Radar Scanner Activated - metal.it
What is Acumen Pharmaceuticals Inc. company’s growth strategyAchieve rapid returns with smart investment plans - jammulinksnews.com
How does Acumen Pharmaceuticals Inc. compare to its industry peersAchieve breakthrough financial results - jammulinksnews.com
What institutional investors are buying Acumen Pharmaceuticals Inc. stockFree Investment Timing Strategies - jammulinksnews.com
What is the dividend policy of Acumen Pharmaceuticals Inc. stockRapidly expanding wealth - jammulinksnews.com
How many analysts rate Acumen Pharmaceuticals Inc. as a “Buy”Overwhelming financial success - jammulinksnews.com
What is the risk reward ratio of investing in Acumen Pharmaceuticals Inc. stockConsistent high-yield stocks - jammulinksnews.com
Acumen Pharmaceuticals Inc. Stock Performance After Earnings: Historical InsightsFree Stock Selection - Newser
Is Acumen Pharmaceuticals Inc. a good long term investmentHigh-velocity capital appreciation - PrintWeekIndia
Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up - insights.citeline.com
What analysts say about Acumen Pharmaceuticals Inc. stockMarket-beating returns - PrintWeekIndia
Is Acumen Pharmaceuticals Inc. stock overhyped or has real potentialAccelerated profit realization - jammulinksnews.com
How high can Acumen Pharmaceuticals Inc. stock price go in 2025Free Daily Trading Room Entry - jammulinksnews.com
Does Acumen Pharmaceuticals Inc. stock pay reliable dividendsSuperior capital gains - jammulinksnews.com
Finanzdaten der Acumen Pharmaceuticals Inc-Aktie (ABOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):